Howard L. Petterson

The recent announcement by the Food and Drug Administration (FDA) regarding unapproved thyroid medications has created a complex and, at times, contradictory situation for both patients and healthcare providers. On one hand, the agency has issued a strong warning about the safety risks associated with these drugs, primarily a category of "animal-derived thyroid" (ADT) products. On the other hand, the FDA has stated its intention to "ensure access" to these very same medications, at least for a transitional period. This dual message reflects the delicate balance the FDA must strike between its mandate to ensure public safety and its responsibility…

The story of a man who was hospitalized with hallucinations after following dietary advice from an artificial intelligence chatbot has brought the risks of relying on unverified digital sources for medical guidance into sharp focus. The individual, who had asked ChatGPT for a low-sodium diet plan, experienced severe health complications that experts have linked to the bot's uncritical recommendations. This incident serves as a stark and sobering reminder that while AI can be a powerful tool, it lacks the foundational knowledge, context, and ethical safeguards necessary for providing health and wellness information. Its output is a reflection of the data…

The recent declaration from the Food and Drug Administration (FDA) concerning non-approved thyroid treatments has led to a complicated and sometimes inconsistent scenario for both patients and medical professionals. The agency has issued a significant alert about the potential safety hazards linked to these medications, particularly a type of "animal-derived thyroid" (ADT) products. At the same time, the FDA has expressed its plan to "maintain accessibility" to these exact medications, at least for a temporary phase. This dual communication highlights the fragile equilibrium the FDA must maintain between its duty to safeguard public health and its obligation to avoid disrupting…